Anondita Medicare IPO

Founded in March 2024, Anondita Medicare Limited is a Noida-based manufacturer specializing in flavored male condoms under its flagship brand “COBRA.” With an annual production capacity of 562 million condoms, the company serves a wide international customer base across Southeast Asia, Africa, and the Middle East. Anondita Medicare plays an active role in supporting public health and family planning by partnering with global health organizations, NGOs, and governments.

The company has built a strong distribution network, ensuring efficient delivery across markets through collaborations with wholesalers, retailers, and e-commerce platforms. It is also a key supplier to government health programs and institutions, reinforcing its presence in essential medical supply chains. As of July 31, 2025, Anondita Medicare employed 280 people.

Anondita Medicare IPO Strengths

• The company’s revenue from operations has grown from ₹23.09 crore in FY22 to ₹77.13 crore in FY25, while profit after tax rose from ₹1.58 crore to ₹16.42 crore over the same period, indicating a strong growth trajectory and increasing profitability.
• Anondita Medicare is a well-established manufacturer of male and female condoms under several brands, including the popular ‘Cobra’ brand, and has diversified into surgical gloves, expanding its addressable market.
• The company’s state-of-the-art facility in Noida is supported by 11 existing manufacturing lines and modern technology, enabling operational efficiency and scalable production capacity.
• Anondita Medicare has been expanding both within India and internationally, supplying government, institutional, and retail clients in multiple states and export destinations.
• Strict quality control systems, adherence to international standards, and relevant certifications support product reliability and repeat customer orders.
• With a track record of supplying to central and state government agencies, health departments, and army hospitals, the company benefits from reputation and recurring institutional demand.
• Collaborations with a network of stockists, distributors, and raw material suppliers ensure business continuity and prompt fulfillment of orders, both directly and through subsidiaries.

Anondita Medicare IPO Risks

• A significant portion of revenue comes from just the top ten customers. Loss of key clients or reduced demand could seriously impact business performance.
• Most sales are concentrated in Delhi, Uttar Pradesh and Haryana. Adverse developments in these markets could disproportionately affect overall results.
• Some company assets, licenses and contracts have not yet been fully transferred out of the promoter’s sole proprietorship into the new public limited entity, introducing potential legal and operational delays.
• The company’s subsidiary has posted losses in past years and may require additional funding or investment write-offs, which could strain resources and profitability.
• Failure in quality control or defective products, especially condoms, could result in reputational damage, regulatory scrutiny and costly product recalls.
• Significant business comes from supplying government and institutional orders, which are subject to tenders, policy changes and pricing controls.
• The business depends on efficient working capital management. Any delays in collections or mismanagement of inventory and cash flows could impact liquidity.